Back to News
Market Impact: 0.25
Photocure ASA: Results for the third quarter of 2026
Source: PR Newswire
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Photocure reported Q3 2026 Hexvix/Cysview revenue of NOK 134.2 million, essentially unchanged from NOK 134.1 million in Q3 2025. Adjusted EBITDA was NOK 18.5 million versus NOK 18.9 million a year earlier. The article excerpt ends before detailing the company’s updated 2026 expectations.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
-0.05
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Asian shares fall as Alphabet earnings miss drags Wall St futures lower